These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17191919)

  • 1. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6.
    Wu ZL; Aryal P; Lozach O; Meijer L; Guengerich FP
    Chem Biodivers; 2005 Jan; 2(1):51-65. PubMed ID: 17191919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis.
    Guengerich FP; Sorrells JL; Schmitt S; Krauser JA; Aryal P; Meijer L
    J Med Chem; 2004 Jun; 47(12):3236-41. PubMed ID: 15163202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis.
    Wu ZL; Podust LM; Guengerich FP
    J Biol Chem; 2005 Dec; 280(49):41090-100. PubMed ID: 16215230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidation of indole by cytochrome P450 enzymes.
    Gillam EM; Notley LM; Cai H; De Voss JJ; Guengerich FP
    Biochemistry; 2000 Nov; 39(45):13817-24. PubMed ID: 11076521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and kinase inhibitory activity of novel substituted indigoids.
    Beauchard A; Laborie H; Rouillard H; Lozach O; Ferandin Y; Le Guével R; Guguen-Guillouzo C; Meijer L; Besson T; Thiéry V
    Bioorg Med Chem; 2009 Sep; 17(17):6257-63. PubMed ID: 19665384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Random mutagenesis of human cytochrome p450 2A6 and screening with indole oxidation products.
    Nakamura K; Martin MV; Guengerich FP
    Arch Biochem Biophys; 2001 Nov; 395(1):25-31. PubMed ID: 11673862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants.
    Sansen S; Hsu MH; Stout CD; Johnson EF
    Arch Biochem Biophys; 2007 Aug; 464(2):197-206. PubMed ID: 17540336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation of the indigo precursor indican in genetically engineered tobacco plants and cell cultures.
    Warzecha H; Frank A; Peer M; Gillam EM; Guengerich FP; Unger M
    Plant Biotechnol J; 2007 Jan; 5(1):185-91. PubMed ID: 17207267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors.
    Beauchard A; Ferandin Y; Frère S; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T
    Bioorg Med Chem; 2006 Sep; 14(18):6434-43. PubMed ID: 16759872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK-3-selective inhibitors derived from Tyrian purple indirubins.
    Meijer L; Skaltsounis AL; Magiatis P; Polychronopoulos P; Knockaert M; Leost M; Ryan XP; Vonica CA; Brivanlou A; Dajani R; Crovace C; Tarricone C; Musacchio A; Roe SM; Pearl L; Greengard P
    Chem Biol; 2003 Dec; 10(12):1255-66. PubMed ID: 14700633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
    Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
    J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aryl hydrocarbon receptor response to indigoids in vitro and in vivo.
    Peter Guengerich F; Martin MV; McCormick WA; Nguyen LP; Glover E; Bradfield CA
    Arch Biochem Biophys; 2004 Mar; 423(2):309-16. PubMed ID: 15001395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3.
    Efstathiou A; Gaboriaud-Kolar N; Smirlis D; Myrianthopoulos V; Vougogiannopoulou K; Alexandratos A; Kritsanida M; Mikros E; Soteriadou K; Skaltsounis AL
    Parasit Vectors; 2014 May; 7():234. PubMed ID: 24886176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of amino acid residues involved in 4-chloroindole 3-hydroxylation by cytochrome P450 2A6 using screening of random libraries.
    Zhang ZG; Liu Y; Guengerich FP; Matse JH; Chen J; Wu ZL
    J Biotechnol; 2009 Jan; 139(1):12-8. PubMed ID: 18984015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based optimization of oxadiazole-based GSK-3 inhibitors.
    Lo Monte F; Kramer T; Gu J; Brodrecht M; Pilakowski J; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
    Eur J Med Chem; 2013 Mar; 61():26-40. PubMed ID: 22749643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death.
    Ribas J; Bettayeb K; Ferandin Y; Knockaert M; Garrofé-Ochoa X; Totzke F; Schächtele C; Mester J; Polychronopoulos P; Magiatis P; Skaltsounis AL; Boix J; Meijer L
    Oncogene; 2006 Oct; 25(47):6304-18. PubMed ID: 16702956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
    Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
    Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
    Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
    J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.
    Vougogiannopoulou K; Ferandin Y; Bettayeb K; Myrianthopoulos V; Lozach O; Fan Y; Johnson CH; Magiatis P; Skaltsounis AL; Mikros E; Meijer L
    J Med Chem; 2008 Oct; 51(20):6421-31. PubMed ID: 18816110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis.
    Xingi E; Smirlis D; Myrianthopoulos V; Magiatis P; Grant KM; Meijer L; Mikros E; Skaltsounis AL; Soteriadou K
    Int J Parasitol; 2009 Oct; 39(12):1289-303. PubMed ID: 19445946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.